- 作者: Jonas Holst Wolff & Jacob Giehm Mikkelsen
- 作者服務機構: Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000, Aarhus C, Denmark
- 中文摘要:
- 英文摘要:
Viruses are naturally endowed with the capacity to transfer genetic material between cells. Following early skepticism,
engineered viruses have been used to transfer genetic information into thousands of patients, and genetic therapies
are currently attracting large investments. Despite challenges and severe adverse efects along the way, optimized
technologies and improved manufacturing processes are driving gene therapy toward clinical translation. Fueled by
the outbreak of AIDS in the 1980s and the accompanying focus on human immunodefciency virus (HIV), lentiviral
vectors derived from HIV have grown to become one of the most successful and widely used vector technologies. In
2022, this vector technology has been around for more than 25 years. Here, we celebrate the anniversary by portraying the vector system and its intriguing properties. We dive into the technology itself and recapitulate the use of lentiviral vectors for ex vivo gene transfer to hematopoietic stem cells and for production of CAR T-cells. Furthermore, we
describe the adaptation of lentiviral vectors for in vivo gene delivery and cover the important contribution of lentiviral
vectors to basic molecular research including their role as carriers of CRISPR genome editing technologies. Last, we
dwell on the emerging capacity of lentiviral particles to package and transfer foreign proteins - 中文關鍵字:
- 英文關鍵字: HIV, Lentivirus, Lentiviral vectors, Integrase-defective lentiviral vectors, IDLV, Gene therapy, Gene editing, Genome engineering, CRISPR